Endocrinology wRVU Compensation in 2026: Benchmarks, Telehealth Models, Panel Size, and What to Ask Before You Sign

Endocrinology is consistently among the lowest-compensated specialties per Medscape 2024-2026 alongside infectious disease and pediatrics. The structural reasons are well understood: cognitive specialty with limited procedural revenue, complex chronic disease management that does not fit well into volume-based productivity models, and significant time-per-encounter requirements for diabetes care, thyroid management, and hormonal disorders. The countervailing reality is that endocrinologists are in significant shortage — wait times for new endocrinology consults often exceed 6 months — and that shortage gives individual endocrinologists negotiating leverage that comp data does not fully reflect.

If you are an endocrinologist evaluating a contract — finishing fellowship, switching practices, or considering a telehealth-heavy model — here is what the 2026 market actually looks like and how to use the leverage you have.

What the 2026 endocrinology benchmarks actually are

Based on MGMA 2025 data, the median endocrinologist produces approximately 4,400 wRVUs annually at $50 per wRVU. Total compensation at the median runs $235,000-$275,000.

The 75th percentile endocrinologist produces around 5,600 wRVUs annually. The 90th percentile is 7,000 — typically reflecting either a high-volume diabetes-focused practice or a thyroid-heavy practice with significant procedural billing (thyroid biopsy, thyroid ultrasound).

Endocrinology is largely cognitive and not significantly affected by the 2026 CMS efficiency adjustment.

The three endocrinology contract traps

Volume targets that compress diabetes care quality. Endocrinology contracts often include language tying compensation to patient volume — '15-18 patients per day' or '3,200+ patient encounters annually.' These targets compress the time-per-encounter required for sustainable diabetes care. A new diabetes consultation realistically requires 60 minutes; a follow-up requires 20-30 minutes. Volume targets that imply 15-18 patients per day require visit times that are below what is clinically sustainable for complex endocrine pathology.

When you compress visit time, two things happen: clinical outcomes deteriorate, and you generate more documentation work in less time. Both lead to burnout. Negotiate for visit time slots that match the clinical complexity of your patient panel.

Telehealth split that quietly caps in-person revenue. Many endocrinology contracts now include language defining a percentage of work that must be in-person versus telehealth. The split matters — telehealth visits often pay slightly less per encounter than in-person visits in commercial payer mix, and the telehealth percentage can be set in ways that limit your scheduling flexibility without offering real workload benefit.

Ask explicitly: what is the telehealth percentage requirement, who decides which visits are in-person versus telehealth, and is there flexibility to adjust the split based on patient preference and clinical appropriateness?

Panel size language that ignores the realities of endocrine care. Endocrinology contracts sometimes include language requiring you to maintain a defined panel size — '1,500 active patients' or 'open new patient slots within 4-6 weeks.' These targets rarely match the reality of endocrine care, where complex patients require longer visits and more between-visit work (lab review, medication adjustments, communication with primary care).

Negotiate for panel sizes that reflect the clinical complexity. A 1,500-patient endocrinology panel is materially different from a 1,500-patient family medicine panel.

What fair endocrinology contract language looks like

On the wRVU structure: a threshold at or below the 50th percentile (around 4,400 wRVUs) with a rate at or above $50/wRVU. Given the supply-demand imbalance in endocrinology, ask for above-median rates ($52-$55/wRVU is reasonable to request).

On visit time: defined visit time slots that match clinical complexity (60 minutes for new diabetes consultations, 30 minutes for complex follow-ups, 20 minutes for stable thyroid follow-ups).

On telehealth: defined telehealth percentage with flexibility for clinical appropriateness and patient preference.

On panel size: explicit upper bound on panel size with a renegotiation process if patient demand pushes the panel higher.

What to ask before you sign

Four specific questions worth getting answered in writing before you commit to an endocrinology contract:

1. What is the per-wRVU rate, and how does that compare to the MGMA 2025 median of $50/wRVU? Given the supply-demand imbalance in endocrinology, can the rate be negotiated above median?
2. What are the visit time slots for new and follow-up consultations, and do those slots match the clinical complexity of complex endocrine pathology?
3. What is the telehealth percentage requirement, who decides which visits are in-person versus telehealth, and is there flexibility for clinical appropriateness?
4. What is the maximum panel size or new consult demand I will be expected to manage, and what happens if patient demand exceeds that maximum?

These are reasonable questions. The shortage of endocrinologists gives you leverage that other specialties do not have. Most endocrinologists do not use that leverage because they do not realize they have it.

Want to know how your specific endocrinology contract compares to these benchmarks? FairRVU runs the full analysis in 60 seconds — wRVU rate vs market, visit time analysis, telehealth structure review, and panel size evaluation. Your contract is permanently deleted after processing.